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Abstract
The bone marrow is a preferential site for both reactive and neoplastic histiocytic proliferations. The differential diagnosis ranges
from reactive histiocyte hyperplasia in systemic infections, vaccinations, storage diseases, post myeloablative therapy, due to
increased cell turnover, and in hemophagocytic lymphohistiocytosis, through extranodal Rosai-Dorfman disease to neoplasms
derived from histiocytes, including histiocytic sarcomas (HS), Langerhans cell histiocytoses (LCH), Erdheim-Chester disease
(ECD), and disseminated juvenile xanthogranuloma (JXG). One of the most important recent developments in understanding the
biology of histiocytic neoplasms and in contributing to diagnosis was the detection of recurrent mutations of genes of the Ras/
Raf/MEK/ERK signaling pathway, in particular the BRAFV600E mutation, in LCH and ECD. Here, we summarize clinical and
pathological findings of 17 histiocytic neoplasms that were presented during the bone marrow symposium and workshop of the
18th European Association for Haematopathology (EAHP) meeting held in Basel, Switzerland, in 2016. A substantial proportion
of these histiocytic neoplasms was combined with clonally related lymphoid (n = 2) or myeloid diseases (n = 5, all ECD). Based
on the latter observation, we suggest excluding co-existent myeloid neoplasms at initial staging of elderly ECD patients. The
recurrent nature of Ras/Raf/MEK/ERK signaling pathway mutations in histiocytic neoplasms was confirmed in 6 of the 17
workshop cases, illustrating their diagnostic significance and suggesting apotential target for tailored treatments.
Keywords Bone marrow biopsy . Erdheim-Chester disease .
Histiocytic sarcoma . Mutation . Myeloid neoplasm . EAHP
workshop
Introduction to histiocytic neoplasms
involving the bone marrow
The bonemarrow (BM) symposium of the 18thmeeting of the
European Association for Haematopathology (EAHP) in
Basel in September 2016 (EAHP 2016) was dedicated to
non-lymphoid/non-myeloid cell proliferations in the BM, in-
cluding histiocytes, mast cells, and dendritic cells; the last
were summarized elsewhere [1]. In the current paper, we sum-
marize the cases of histiocytic neoplasms involving the BM
which were submitted to the workshop.
The BM, as a source of histiocytic precursor cells and a
major home to tissue histiocytes and macrophages, which
constitute approximately 10% of its microenvironment, is
commonly affected by reactive and neoplastic histiocytic
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disorders [2], the latter occurring either primarily or as sec-
ondary spread. Histiocytes are usually dispersed throughout
the BM (Fig. 1), located particularly in the erythropoietic
islands as nurse-like cells. They are inconspicuous unless they
are increased in number, enlarged, show a disturbed location
(clustering, bone apposition), or because of altered cytoplasm
due to phagocytosis [3]. Non-neoplastic diffuse histiocyte ac-
cumulations in the BM are associated with increased cellular
turnover (sea-blue/pseudo-Gaucher cells, e.g., in myeloprolif-
erative neoplasms, idiopathic thrombocytopenic purpura, thal-
assemia), systemic infections, bacillus Calmette-Guérin vac-
cination, myeloablative therapy (foamy cells), storage disor-
ders, accompanying plasma cell neoplasms (crystal storing
histiocytosis), and T cell proliferations in hemophagocytic
lymphohistiocytosis (HLH). Several reactive examples were
submitted to the EAHP workshop but are not addressed in this
report, which focuses on BM involvement by neoplasms of
histiocytic origin.
Histiocytoses, i.e., neoplasms derived from histiocytes, are
rare disorders characterized by the accumulation of macro-
phages, dendritic cells, or monocyte-derived cells in various
tissues and organs. Except for clear-cut malignant prolifera-
tions composed of atypical cells showing an infiltrative/
destructing growth pattern, tumor necrosis, anisocytosis,
anisokaryosis, increased nucleo-cytoplasmic ratio, chromatin
abnormalities, hypereosinophilic nucleoli, and brisk or atypi-
cal mitotic activity, the distinction of histiocytoses from reac-
tive histiocytic proliferations such as those listed above might
be challenging, since some histiocytoses may display only
minimal morphological deviation. The importance of the in-
tegration of clinical (e.g., a syndromic context) and radiologic
features (e.g., osteolysis, Bhairy kidney^; see later) in the di-
agnosis cannot be overemphasized. The diagnostic value of
the aberrant expression of various mutant or phosphorylated
proteins, such as V600E mutant BRAF [4], phosphorylated
extracellular signal-regulated kinases (ERK1/2) [5], or, as re-
cently suggested, the enzymatic subunit of the polycomb re-
pressive complex 2 (EZH2) [6], still requires validation, but
seems promising.
One of the most important developments contributing to
the understanding of the biology of histiocytic neoplasms
was the detection of recurrent mutations of genes of the Ras/
Raf/MEK/ERK signaling pathway, in particular, the
BRAFV600E mutation in Langerhans cell histiocytosis (LCH)
and Erdheim-Chester disease (ECD) [7, 8]. Mutually exclu-
sive with BRAFV600E, additional genetic aberrations in the
same pathway include mutations of MAP2K1 and ARAF in
LCH [9, 10], and KRAS, NRAS, and PIK3CA and—very rare-
ly—ARAF in ECD [11, 12]. Recently, recurrent oncogenic
mutations of components of the MAPK pathway, including
KRAS, SMAD4, and MAP2K1 (but not BRAF), have been
reported in a few cases of, particularly extranodal, Rosai-
Dorfman disease (RDD) [11, 13, 14], challenging its assumed
non-neoplastic nature in extranodal presentation.
Interestingly, individuals suffering from the autoimmune lym-
phoproliferative syndrome, lymphoproliferative disorders as-
sociated with germline FAS and RASmutations, can also show
RDD-like features [15, 16], and new concepts (see later) of
RDD suggest that nodal and extranodal forms may represent
different disorders, which may explain the discrepant evi-
dence for both a non-clonal and clonal nature of RDD lesions.
A novel classification of histiocytoses has been recent-
ly proposed [12], defining five subgroups based on clini-
cal and/or phenotypical criteria, namely (1) Langerhans-
type histiocytoses; (2) cutaneous and mucocutaneous
histiocytoses; (3) malignant histiocytoses; (4) the group
of HLH/macrophage activation syndromes, which is de-
fined by a combination of symptoms, morphological find-
ings and laboratory tests [17]; and finally (5) RDD. This
classification differs slightly from the current World
Health Organization (WHO) classification of histiocytic
and dendritic neoplasms, which is primarily based on
morphological and phenotypical criteria [18] and recog-
nizes (1) histiocytic sarcomas, (2) tumors derived from
Langerhans cells (LC), (3) indeterminate dendritic cell
tumors, (4) interdigitating and (5) follicular dendritic cell
sarcomas, (6) fibroblastic reticular cell tumors, (7) dis-
seminated juvenile xanthogranulomas (JXG), and (8)
ECD, while RDD has not been included in this
classification.
RDD is a heterogeneous entity, and classic cases (single or
regional lymph node involvement with a self-limiting clinical
course) and extranodal cases probably represent distinct dis-
orders. For now, it is recommended to make a clear distinction
between these two forms [12]. Accumulation of large histio-
cytic cells with hypochromic, roundish nuclei with often
prominent nucleoli and pale cytoplasm with abundant
emperipolesis is highly characteristic of RDD. RDD
Fig. 1 Histological appearance and distribution of histiocytic cells in a
normal bone marrow highlighted by a CD68 stain, × 360. Note a
Bstellate^ cell with dendroid protrusions surrounded by erythroid
precursors in the center. Since CD68 stains lysosomes, the staining
appears dotted
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histiocytes express S100, CD4, CD11c, CD14, CD68, and
CD163, while CD1a and/or langerin is negative. Involved
tissues usually contain abundant polyclonal plasma cells, par-
ticularly IgG4-positive types, B cells, and increased fibers.
RDD can also be observed at several extranodal sites includ-
ing the bones/BM [19, 20]. In our personal observations, RDD
of the bone accounts for approximately 0.3% of all symptom-
atic bone lesions [Tzankov unpublished]. A RDD case with
aggressive morphological features, involvement of multiple
lymph nodes and diffuse skeletal spread was submitted to
the workshop (Table 1, case 15).
JXG, especially the solitary dermal JXG, is probably the
most common histiocytosis [12, 21] and represents a benign
proliferative disorder of children. It is typically characterized
by the presence of BTouton^ giant cells and a distinct, but non-
specific immunophenotype (FXIIIa+/CD1a-/CD14+/CD68+/
S100±). Mutations of MAPK pathway genes in JXG are in-
creasingly reported [22–24]. There is an association with neu-
rofibromatosis type 1, especially for the disseminated form
[25]. Disseminated JXG is much rarer than the solitary form.
It can affect the BM, and an interesting case of an atypical
histiocytic proliferation with JGX phenotype after remission
of T cell lymphoblastic leukemia (T-ALL) (Table 1, case 6)
and one of HLH associated with disseminated JXG (Table 1,
case 17) were submitted to the workshop.
LCH is a proliferation of LC with characteristic mor-
phology (oval cells with abundant slightly eosinophilic
cytoplasm with central grooved/indented nuclei with fine
chromatin), ultrastructure (Birbeck granules), and pheno-
type (CD1a+/CD68+/langerin+/S100+), accompanied by
eosinophils, lymphocytes, and macrophages, as well as
osteoclast-type giant cells. Clinical presentation varies
from an asymptomatic solitary lesion to a lethal multisys-
tem disease [26]. LCH typically involves bones and the
skull bones are the most frequently affected. The debate
on the nature of LCH is now resolved by the discovery of
the recurrent mutually exclusive BRAFV600E [7] or
MAP2K1 mutations in over 80% of cases [9]. As already
mentioned, this was a milestone towards understanding
the pathobiology of histiocytic neoplasms in general.
Several recent findings suggest that LCH has a heteroge-
neous histogenesis [27]. Multisystemic cases may be neo-
plastic disorders derived from aberrant hematopoietic pro-
genitor cells that have acquired a BRAFV600E mutation,
which may explain the multifocal bone/BM involvement
[28]. Indeed, in seven patients suffering from LCH, the
BRAFV600E mutation was also detected in their CD34+
hematopoietic progenitor cell pool [29]. One patient with
metachronous LCH and Hodgkin lymphoma bearing the
BRAFV600E mutation has been reported [30] and there is
evidence from a case submitted to the workshop (Table 1,
case 16) as a mixed LC/non-LC sarcoma—as suggested
by the submitter—that has been classified by the panel as
LC sarcoma with aberrant expression of CD163. These
cases illustrate the plasticity of LCH histogenesis.
On the other hand, skin-limited LCH in children is proba-
bly derived from tissue-restricted LC precursors, in keeping
with the benign behavior of this variant [31]. Patients with low
risk and unifocal LCH lack mutated progenitor cells in the
peripheral blood, pointing to heterogeneity in the cell of origin
of this disease and the prognostic importance of the particular
affected cellular pool involved by the respective driver muta-
tion [29, 31].
HS has a particularly pronounced association with neo-
plasms derived from other non-histiocytic lineages, since a
substantial number of cases is associated with other
hematolymphoid tumors [especially follicular lymphomas
(FL); Table 1, case 5] [32–35] and HS may display B or T
cell clonality [35, 36]. HS can also arise in mediastinal
germ cell tumors [37, 38] as illustrated by case 4. The
distinction of HS with BM involvement from acute mye-
loid leukemia (AML) with monocytic differentiation is dif-
ficult and depends on integration of morphology (large,
usually pleomorphic cells > 20 μm in diameter with abun-
dant cytoplasm [18]) and phenotypic characteristics, par-
ticularly the absence of the myeloid markers CD33 and
myeloperoxidase and positivity for at least one histiocytic
marker (i.e., either CD4, CD11c, CD14, CD68, CD163, or
lysozyme), considered as a prerequisite for the diagnosis of
HS, as shown in case 1. Druggable mutations of genes of
the Ras/Raf/MEK/ERK signaling pathway are recurrent in
HS in general [39, 40], as illustrated by several cases sub-
mitted to the 2016 EAHP workshop on histiocytic neo-
plasms involving the lymph nodes [35].
ECD is the most intriguing histiocytic disorder affecting
the BM from the panel’s point of view. ECD is a histiocytic
neoplasm involving the skeleton, particularly the long bones,
with a distinctive radiological presentation of symmetrical di-
aphyseal and metaphyseal cortical bone sclerosis (Fig. 2a), the
cardiovascular system, the lungs, the retroperitoneum with so-
called coated aorta and hairy kidney, the CNS, and the skin. It
is composed of foamy histiocytes (FXIIIa+/CD14+/CD68+/
CD163+/langerin−) and Touton giant cells. In over 70% of
cases, targetableMAPKpathway or PI3K-AKT pathway gene
mutations can be detected [11, 12, 41]. As in LCH, the mul-
tisystem involvement by ECD and evidence from 4/7 cases
submitted to this workshop, which showed concurrent or
metachronous occurrence of myeloid neoplasms [AML or
chronic myelomonocytic leukemia (CMML)], suggest that,
like multisystemic LCH, ECDmay also be a neoplastic hema-
topoietic disorder derived from aberrant progenitor cells
which in this case have acquired MAPK pathway or PI3K-
AKT pathway gene mutations.
The next section summarizes the most important features of
the submitted workshop cases and focuses on a few important
practical lessons learned, based on these cases.
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Cases and discussion
Among a total of 68 workshop cases of histiocytic prolifera-
tions in the BM, 17 were considered to be histiocytic neo-
plasms. Table 1 summarizes these cases.
Two of the 9 workshop submissions with ECD proved to
be the same patient (case 12) that had been treated in different
hospitals. All eight patients with ECD presented with multiple
bone lesions and varying involvement of soft tissues, mainly
retroperitoneum and mesentery, lungs, and/or orbital fat (case
7). Clinical symptoms consisted of localized or generalized
bone pain, dyspnea, proptosis, or B symptoms. The BM
showed accumulations of bland histiocytes, including cells
with foamy cytoplasm, in an often-fibrotic background (Fig.
2b, case 12). The histiocytes expressed CD14, CD68, CD163,
FXIIIa and fascin (Fig. 2c). Protein expression of BRAFV600E
was shown in 2 mutant cases (cases 9 and 13). Two cases were
focally S100 positive (Fig. 2d, e; cases 10 and 13), and one of
the S100-positive cases displayed some degree of
hemophagocytosis (case 10); CD1a was always negative.
When performed, cytogenetics was unremarkable, while the
BRAFV600E mutation was found in 4 of 7 tested cases (57%),
and 1 case (case 12) displayed the pathogenic NRASQ61R mu-
tation [42].
Remarkably, 4/7 ECD patients suffered from synchronous
or metachronous myeloid neoplasms, CMML (n = 2, cases 11
and 12) and AML with at least phenotypic monocytic differ-
entiation (n = 2, cases 13 and 14), and one patient suffered
from an undefined myeloid neoplasm with accompanying
HLH, which was considered by the submitter to represent an
ECD (n = 1, case 10). These patients were all male and more
than a decade older (mean age 65.4 years), than those suffer-
ing from ECD alone with a male:female ratio of 2:1 and a
mean age of 51.3 years. All four cases had a BRAFV600E or
NRASQ61R mutation and showed the same mutation in the
ECD lesions and in the myeloid neoplasm. These were twice
combined with additional mutations, including TET2 and
SRSF2 mutations in a CMML case, and ASXL1, TET2, and
U2AF1 mutations in the disseminated case of an undefined
myeloid neoplasm accompanied by HLH (Fig. 3a, b; case 10).
The exact classification of the latter was difficult because of
the rapid death of the patient due to disseminated intravascular
coagulation and HLH. In addition, the histiocytes of this case
were S100 positive and displayed hemophagocytic activity, so
that, despite suggesting ECD in many aspects, the case was
considered by the panel to be better classified as HLH associ-
ated with undefined myeloid neoplasm.
Treatment of the ECD cases included mainly steroids,
interferon-α, methotrexate, and chemotherapy. The treatment
and the prognosis in composite cases were mainly determined
by the accompanying myeloid neoplasm. Noticeably, the case
bearing the highest number of mutations, particularly of mu-
tations known to be associated with poor prognosis in myeloidTa
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disorders (e.g., ASXL1 and U2AF1) [43], had a very aggres-
sive clinical behavior.
Three cases considered to represent Btrue^ HS were sub-
mitted to the workshop (cases 1, 2, and 3). Shared clinical
features of these cases included involvement of the liver
and/or the spleen and systemic symptoms such as fever, fa-
tigue, weight loss, and/or hemophagocytosis. The BM and
other involved tissues showed aggregates of large bizarre his-
tiocytes with abundant pale cytoplasm and pleomorphic nu-
clei with occasionally pronounced nucleoli and numerous mi-
toses (Fig. 4a, b). The tumor cells expressed CD68 and
CD163 (Fig. 4c, d), and lysozyme and fascin, when tested.
One of these cases (case 1) illustrated the sometimes challeng-
ing differentiation between HS and other myeloid malignan-
cies with monocytic/histiocytic differentiation. The tumor
cells in this case were rather small (< 20 μm) and monotonous
and expressed CD33, thereby not fulfilling the morphologic
and phenotypic requirements for HS [12, 18, 44–46]. The case
was therefore reclassified by the panel as AML with mono-
cytic differentiation. One of the other HS cases had clinical
records and showed an aggressive clinical course, dying be-
fore diagnosis (case 3). No genetic aberrations were found in
the HS cases by karyotyping (2/3 cases) or sequencing (21
gene myeloid panel in 1 case). Yet, based on a few studies
with mutational data on HS published to date, the Ras/Raf/
MEK/ERK signaling pathway in HS seems also to be recur-
rently targeted by mutations: the BRAFV600E mutation was
detected in 5 of 8 HS [47]; a case of BRAFF595L mutation
along with mutant HRAS [48] has been documented;
BRAFG466R/G464V/N581S mutations and KRAS, PTPN11,
TP53, PTEN, and PIK3CA were recently published [49].
Interestingly, these types of BRAF mutations have been
Fig. 2 a Characteristic imaging appearance of Erdheim-Chester disease
(ECD) on whole body scintigraphy and MRI (case 8). b Conventional
H&E histopathology of an ECD lesion (× 360, case 12). c Membranous
positivity for CD14 (× 400, case 7). d Occasional partial positivity for
S100 (× 360, case 13). eCharacteristic granular positivity for BRAFV600E
in a mutant case (× 360, case 13)
Fig. 3 a Case 10. Diffuse
pulmonary infiltration by a
xanthomatous proliferation
composed of Erdheim-Chester
disease-like histiocytes (insert). b
Bone marrow infiltration by an
undefinedmyeloid neoplasmwith
histiocytic appearance (area be-
tween arrows) and visible
hemophagocytosis, × 360
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reported in carcinoma and melanoma, but not in other histio-
cytic tumors [11]. Very recently, the report of the 2016 EAHP
workshop on histiocytic neoplasms involving the lymph
nodes documented 7 HS, of which 2 had BRAFV600E-, one a
TP53 and one a MAP2K1 mutation (along with BCL2,
BCL10, CDKN1B, CKIT) [35]. Since the prognosis of HS is
dismal with current treatment strategies and several of the
above-mentioned mutations are actionable, their detection
and specific targeting yield treatment potential, as already
suggested by single-case observations [35, 39, 40].
Three histiocytic neoplasms occurred in the context of oth-
er neoplastic diseases. Case 4 represented the rare, yet histor-
ically well-documented combination of a HS and a mediasti-
nal germ cell tumor. The patient presented with pain under the
left rib arch, bicytopenia, splenomegaly, and a mediastinal
tumor, consisting of a mixed germ cell tumor (teratoma and
yolk sack tumor). The spleen and the BM of the patient were
involved by concomitant HS with prominent hemophagocytic
activity (Fig. 5a). Interphase FISH, applying a dual-color
break-apart probe for the ETV6 locus at 12p13.2, showed
signals suggestive of i(12p) in both neoplastic components,
thus proving their clonal relationship (Fig. 5a insert). Case 5
illustrated the well-known transformation of FL to HS [33,
34]. Differently from previous cases, the patient presented
with multiple liver lesions due to the HS, and the FL compo-
nent was only found in the staging BM biopsy along with the
HS (Fig. 5b). FISH analysis demonstrated BCL2 rearrange-
ments in both components, proving their relationship. The last
case in this series (case 6) was an atypical histiocytic prolifer-
ation with JXG phenotype involving the BM with subsequent
spread to the skin, liver, spleen, and pancreas, after remission
of T-ALL (Fig. 5c). The BM showed massive involvement by
JXG-like lesions, displacing the hematopoiesis (Fig. 5d).
Attempts to study the molecular relationship of the JXG-like
component with the previous T-ALL that was clonal for the T
cell receptor genes and had a recurrent del(9)(p13) failed since
the histiocytic lesion showed no clonal rearrangement and did
not display del(9)(p13). A possible role of the initial
myelotoxic therapy in the development of the JXG-like le-
sions, similar to documented LC proliferations [50–52], has
to be also taken into consideration in this particular case.
Together with 14 analogous cases submitted to the EAHP
workshop on histiocytic neoplasms involving the lymph
nodes [35], the above cases add further strong evidence in
support of the frequent clonal relationship between mature B
cell lymphomas and T-ALL/lymphoblastic lymphomas on the
one hand and histiocytic neoplasms on the other [33, 34,
53–60]. While transdifferentiation of a neoplastic lymphoid
cell after loss of the lineage transcription program has initially
been proposed as an explanation [33, 45, 54], evidence now
points towards divergent differentiation of a common progen-
itor cell into multiple lineages as an alternative pathogenic
mechanism [34, 58, 60].
Two additional cases deserve special attention because of
specific diagnostic dilemmas. The first one (case 15) was
RDD in a patient with an uncommon generalized presentation
involving multiple lymph nodes and the skeleton (Fig. 6a),
pointing towards the importance of distinguishing classical
RDD cases, with single or regional lymph node involvement
and a self-limiting clinical course, from extranodal cases [12].
The second one (case 16) was thought by the submitter to
represent a mixed LC/non-LC sarcoma since a subset of the
infiltrate expressed LC markers, while other cells expressed
CD163. Yet, both components showed a BRAFV600E mutation
Fig. 4 a Case 3. Histiocytic
sarcoma involving the bone
marrow, × 100. b Detailed view
of atypical large cells with
prominent nucleoli and admixed
eosinophils, × 360. c Positivity
for CD68, × 360. d Positivity for
CD163, × 200
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and were intermingled (Fig. 6b). Therefore, the panel felt that
the diagnosis was LC sarcoma with aberrant expression of
CD163, fitting with the current view of the histogenesis of
Bcomposite histiocytoses^ from a histiocytic cell pool bearing
the BRAFV600E or equivalent mutations and retaining some
plasticity [28, 61, 62].
Finally, a rather prototypic case (case 17) of disseminated
JXG (Fig. 6c, d) with cytogenetic evidence of clonality [63]
that was accompanied by HLH and resolved after HLH pro-
tocol treatment rounded up the workshop. The authors of this
case had comprehensively investigated the important differen-
tial diagnoses of juvenile myelo-monocytic leukemia,
Fig. 5 a Case 4. CD68-positive cells of a HS involving the bone marrow
in a patient suffering from a mediastinal germ cell tumor, displaying three
ETV6 signals on an interphase FISH suggestive of i(12p) (insert),
confirming clonal relationship to the germ cell tumor, × 200. b Case 5.
HS in the bone marrow of a patient with flow cytometrically proven
follicular lymphoma [corresponding to the crushed, small, CD20-
positive (not shown), lymphoid cells seen in the upper right part of the
microphotograph near the insert], displaying rearranged BCL2 signals on
an interphase FISH (insert), indicative for a common clonal origin of both
neoplasms, × 200. c Case 6. Bone marrow involvement by acute T lym-
phoblastic leukemia (T-ALL), × 400. d Atypical histiocytic proliferation
with juvenile xanthogranuloma phenotype (insert: FXIIIa) that developed
8 months after remission of the T-ALL, × 360
Fig. 6 a Case 15. Rosai-Dorman
disease with aggressive features
diffusely spreading to the bone
marrow (insert: S100 staining), ×
360. b Case 16. Langerhans cell
sarcoma in the bone marrow ex-
pressing langerin (upper insert)
and with aberrant expression of
CD163 (lower insert), × 360. c
Case 17. Disseminated juvenile
xanthogranuloma, skin lesion
(×200), associated with d bone
marrow changes with reactive
erythroid hyperplasia and
hemophagocytosis (note
Bstrawberry-like cells^ with
engulfed erythrocytes), × 360
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neurofibromatosis type 1, and familial HLH by targeted mas-
sive sequencing approaches.
Lessons learned
The most remarkable observation of this workshop on neo-
plastic histiocytic disorders involving the BM, and the first
lesson learned, was the high concurrence of ECD andmyeloid
neoplasms, mainly CMML or AML with monocytic/
histiocytic phenotype. Five of the 8 workshop cases of ECD
and analogous lesions involving the BM (56%) showed evi-
dence of mostly clonally related myeloid neoplasms (4 cases).
This new observation was confirmed in an ASH abstract by
Durham et al. [64]. Their series of 190 adult histiocytosis
patients showed co-existing myeloid malignancies in 9.5%,
usually patients with ECD and/or LCH, combined with
myelodysplastic-myeloproliferative neoplasms, classical my-
eloproliferative neoplasms, or myelodysplastic syndromes.
Only general data were provided on co-exist ing
histiocytosis-associated mutations (BRAF, MAP2K1, NRAS,
or KRAS) and myeloid-associated mutations (ASXL1, CALR,
IDH1/2, JAK2, and TET2) in the same patients, without infor-
mation on the tested material or exact combinations of muta-
tions. In our workshop cases, molecular characterization of
both components of these cases provided evidence of the clon-
al relationship between ECD and the concurrent or evolving
myeloid neoplasms, ranging from a single (BRAFV600E or
NRAS Q61R) to multiple shared mutations (ASXL1,
BRAFV600E, TET2, and U2AF1 or BRAFV600E, SRSF2, and
TET2, respectively) in 2 cases each. Since at least some of
these mutations are actionable and patients qualify for tailored
therapies [28], patients have to be tested with gene panels
whenever possible when treatment is planned, remembering
that mutation pattern can change during such targeted thera-
pies [41].
An immediate practical aspect and the second lesson
learned, yet admittedly based on this limited workshop series:
ECD patients with associated myeloid neoplasms were exclu-
sively male and more than a decade older than those affected
by ECD alone, while the latter showed the age and sex distri-
bution reported by the WHO [18]. Based on this observation,
we suggest excluding co-existent myeloid neoplasms at the
initial staging of elderly male patients suffering from ECD.
As expected in composite cases, the treatment and the prog-
nosis were mainly determined by the accompanying myeloid
neoplasm.
Observations on the few submitted HS cases reconfirmed
an old lesson learned for this entity: its status as a highly
aggressive neoplasm often accompanied by organomegaly
and hemophagocytosis [12]. Meticulous phenotypic studies
are required to exclude other diseases such as anaplastic lym-
phomas, sarcomas, melanomas, and AML with monocytic/
histiocytic differentiation, which can all mimic HS histopath-
ologically. Among the markers required to be negative, CD33
deserves special attention as a marker precluding the diagnosis
of HS [41, 58, 59], despite not being listed by the WHO in the
current classification [18].
A lesson to be learned from the histiocytic proliferations
combined with FL, germ cell tumors, or T-ALL is to look
systematically for underlying lymphomas in any cases of
HS. B or T cell gene rearrangement studies and FISH can
prove clonal relationship in such instances.
In summary, a spectrum of neoplastic histiocytic disorders
can affect the BM, mainly as multisystem disorders. A sub-
stantial proportion is combined with—mostly—clonally relat-
ed lymphoid or myeloid diseases (particularly ECD).
Applying the WHO criteria and integrating clinical, laborato-
ry, and radiologic findings, classification of the respective en-
tities is usually possible. Yet in HS—lacking disease-defining
clinical, laboratory, radiologic, and molecular features—broad
phenotypic panels must be applied. Deregulation of the Ras/
Raf/MEK/ERK signaling pathway and, to a lesser extent, of
the PI3K pathway by recurrent mutations is of pathogenic and
diagnostic importance in histiocytic neoplasms, as illustrated
by many cases presented at the workshop. Therefore, exten-
sive mutational screening with properly designed gene panels
is highly recommended, not only for diagnostic but also for
therapeutic purposes.
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